The fact that this news is published in a specialized media such as “Estrategia Empresarial” reinforces the position of VIVEbiotech as a manufacturer of lentiviral vectors in the international market. It also allows the dissemination to a more general public of the Gene Therapy field and of the development of innovative technologies such as LENTISOMA.